These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30531600)

  • 1. Response to Pazopanib in Patients With Relapsed Osteosarcoma.
    Elete KR; Albritton KH; Akers LJ; Basha R; Ray A
    J Pediatr Hematol Oncol; 2020 May; 42(4):e254-e257. PubMed ID: 30531600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
    Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
    BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib in relapsed osteosarcoma patients: report on 15 cases.
    Longhi A; Paioli A; Palmerini E; Cesari M; Abate ME; Setola E; Spinnato P; Donati D; Hompland I; Boye K
    Acta Oncol; 2019 Jan; 58(1):124-128. PubMed ID: 30207179
    [No Abstract]   [Full Text] [Related]  

  • 4. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients.
    Safwat A; Boysen A; Lücke A; Rossen P
    Acta Oncol; 2014 Oct; 53(10):1451-4. PubMed ID: 25143189
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
    Schulte B; Mohindra N; Milhem M; Attia S; Robinson S; Monga V; Hirbe AC; Oppelt P; Charlson J; Helenowski I; Abbinanti S; Cehic R; Okuno S; Van Tine BA; Agulnik M
    Br J Cancer; 2021 Aug; 125(4):528-533. PubMed ID: 34050255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
    Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
    Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
    Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?
    Palmerini E; Torricelli E; Cascinu S; Pierini M; De Paolis M; Donati D; Cesari M; Longhi A; Abate M; Paioli A; Setola E; Ferrari S
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27792. PubMed ID: 31058424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of a radiation-associated extradural osteosarcoma with chemotherapy in an adolescent girl.
    Kellie SJ; Hutchison RE; Robertson JT; Pratt CB
    Med Pediatr Oncol; 1989; 17(6):514-9. PubMed ID: 2586366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.
    Akazawa R; Umeda K; Saida S; Kato I; Hiramatsu H; Sakamoto A; Arakawa Y; Sumiyoshi S; Okamoto T; Moritake H; Adachi S; Takita J
    Jpn J Clin Oncol; 2020 Aug; 50(8):948-952. PubMed ID: 32463097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron Emission Tomography Detects
    Butch ER; Mead PE; Amador Diaz V; Tillman H; Stewart E; Mishra JK; Kim J; Bahrami A; Dearling JLJ; Packard AB; Stoddard SV; Vāvere AL; Han Y; Shulkin BL; Snyder SE
    Cancer Res; 2019 Jun; 79(12):3112-3124. PubMed ID: 31015228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Perin S; Forni C; Fabbri N; Salduca N; Versari M; Smith KV
    Eur J Cancer; 2001 Jan; 37(1):32-8. PubMed ID: 11165127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is CDK9 a promising target for both primary and metastatic osteosarcoma?
    Qin JJ
    EBioMedicine; 2019 Feb; 40():27-28. PubMed ID: 30651218
    [No Abstract]   [Full Text] [Related]  

  • 16. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
    Pérez-Valderrama B; Arranz Arija JA; Rodríguez Sánchez A; Pinto Marín A; Borrega García P; Castellano Gaunas DE; Rubio Romero G; Maximiano Alonso C; Villa Guzmán JC; Puertas Álvarez JL; Chirivella González I; Méndez Vidal MJ; Juan Fita MJ; León-Mateos L; Lázaro Quintela M; García Domínguez R; Jurado García JM; Vélez de Mendizábal E; Lambea Sorrosal JJ; García Carbonero I; González del Alba A; Suárez Rodríguez C; Jiménez Gallego P; Meana García JA; García Marrero RD; Gajate Borau P; Santander Lobera C; Molins Palau C; López Brea M; Fernández Parra EM; Reig Torras O; Basterretxea Badiola L; Vázquez Estévez S; González Larriba JL
    Ann Oncol; 2016 Apr; 27(4):706-11. PubMed ID: 26658889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difference in pre- and postchemotherapy vascular endothelial growth factor levels as a prognostic indicator in osteosarcoma.
    Qu Y; Xu J; Jiang T; Zhao H; Gao Y; Zheng C; Shi X
    J Int Med Res; 2011; 39(4):1474-82. PubMed ID: 21986150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
    Phan AT; Halperin DM; Chan JA; Fogelman DR; Hess KR; Malinowski P; Regan E; Ng CS; Yao JC; Kulke MH
    Lancet Oncol; 2015 Jun; 16(6):695-703. PubMed ID: 25956795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib for second recurrence of osteosarcoma in pediatric patients.
    Umeda K; Kato I; Saida S; Okamoto T; Adachi S
    Pediatr Int; 2017 Aug; 59(8):937-938. PubMed ID: 28685501
    [No Abstract]   [Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience.
    Bacci G; Balladelli A; Palmerini E; Alberghini M; Pollastri P; Galletti S; Mercuri M; Picci P
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):908-12. PubMed ID: 19131777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.